Anxiety Program: Small Molecule to Treat Anxiety Disorders, including GAD and PTSD
GAD: Anxiety disorders, which include include generalized anxiety disorder (GAD), panic disorder and panic attacks, agoraphobia, social anxiety disorder, separation anxiety, and specific phobias, are among the most prevalent of psychiatric disorders in modern society. An estimated 44 million American adults suffer from anxiety disorders. Only about one-third of those suffering from an anxiety disorder receive treatment, even though the disorders are highly treatable.
PTSD: Post-traumatic stress disorder (PTSD) is a mental health problem that some people develop after experiencing or witnessing a life-threatening event, like combat, a natural disaster, a car accident, or sexual assault. Most people who experience such events recover from them, but people with PTSD continue to be severely depressed and anxious for months or even years following the event. The DSM-V diagnostic criteria for PTSD include four symptom clusters: re-experiencing, avoidance, negative alterations in cognition/mood, and alterations in arousal and reactivity. Only two medicines (the selective serotonin reuptake inhibitors sertraline & paroxetine) are approved to treat PTSD, however, they only treat depressive effects of PTSD. Residual PTSD symptoms following treatment is the rule rather than the exception.
Ophidion has an advanced program that is positioned to enter pivotal clinical trials to treat GAD/PTSD, together with a patented companion biomarker diagnostic to select the appropriate patient population for these disorders.